适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Amgen
- 主要终点
- Subject preference
研究概览
简要总结
The purpose of this study was to evaluate subject preference for Aranesp® administered once monthly (i.e., every 4 weeks (Q4W)) or Procrit® administered once weekly (QW).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must have signed written informed consent - Be on Procrit® QW or Q2W for a minimum of 8 weeks - Must currently be on a stable dose of Procrit® (defined as less than 25% change in Procrit® dose over the 4 week period immediately prior to enrollment, with no missed doses) - Have Hgb 10-12 g/dL for at least 4 weeks prior to study start - Have 15 less than GFR less than 89 mL/min/1.73 m2
排除标准
- •Currently receiving investigational erythropoietic agents - Self-injecting at home with Procrit® - Expected to initiate renal replacement therapy (dialysis or transplantation) within 1 year of study start - Have less than 1 year life expectancy
结局指标
主要结局
Subject preference
次要结局
- Subject productivity and subject selection of Aranesp® or Procrit® therapy in the parallel arm portion and at study conclusion.
研究者
相似试验
已完成
4 期
Study to Evaluate Effectiveness of Aranesp®Kidney DiseaseNCT00117130Amgen
已完成
4 期
Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic HemodialysisEnd Stage Renal DiseaseNCT00117104Amgen
已完成
3 期
A Study to Evaluate of the Safety and Effectiveness of Asoprisnil in Treating Women With Uterine FibroidsFibroid UterusMetrorrhagiaUterine FibroidsLeiomyomaMenorrhagiaNCT00152256Abbott239
已完成
3 期
An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD)Kidney DiseaseNCT00124098Amgen
已完成
4 期
A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With AnemiaNeoplasmsAnemiaNCT00117039Amgen1,500